-
Mixed Chimerism and Its Impact on Long-term Failure-free Survival in Aplastic Anemia Patients Undergoing HLA-matched Donor Transplantation
In January 2024, a groundbreaking study spearheaded by Professor Xiaojun Huang from Peking University Institute of Hematology, was featured in the distinguished international journal — Bone Marrow Transplantation . The research, titled “Mixed Chimerism and Its Influence on Long-term Failure-free Survival in Aplastic Anemia Patients Undergoing HLA-Matched Donor Transplantation” delivers new insights into the prognosis…
-
Comparison of Haploidentical Hematopoietic Stem Cell Transplantation with Chemotherapy in Older Adults with Acute Myeloid Leukemia
In 2023, a groundbreaking study spearheaded by Professor XiaoJun Huang from Peking University Institute of Hematology, made its debut in a prestigious international academic journal——Bone Marrow Transplantation. This pivotal research, entitled “Comparison of Haploidentical Hematopoietic Stem Cell Transplantation with Chemotherapy in Older Adults with Acute Myeloid Leukemia” offers a novel perspective on treatment efficacy for…
-
Impacts of Early Therapy Response, Interval to Therapy Interruption, and Cumulative Therapy Interruption Duration on Outcome of Ibrutinib Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia
In July 2023, a groundbreaking study led by Professor Xiaojun Huang from Peking University Institute of Hematology was published in a prestigious academic journal ——Annals of Hematolog. The study, titled “Impacts of Early Therapy Response, Interval to Therapy Interruption, and Cumulative Therapy Interruption Duration on Outcome of Ibrutinib Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia” marks…
-
External validation of the predictive scoring systems formolecular responses in chronic myeloid leukaemia receivinginitial imatinib-therapy
In July 2023, a significant study led by Professor Xiaojun Huang from Peking University Institute of Hematology was published in Leukemia, focusing on chronic myeloid leukemia (CML) treatment with imatinib. This research introduced and validated a predictive scoring system to forecast molecular responses in CML patients. The study, involving an external validation on a cohort…
-
Advancing Understanding of Castleman Disease in China: A Multicenter Retrospective Study
Introduction: Castleman disease (CD) is a rare lymphoproliferative disorder characterized by heterogeneous clinical manifestations and outcomes. Despite its rarity, CD poses significant diagnostic and therapeutic challenges due to its diverse…
-
Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China
Abstract: This retrospective study aimed to delineate the utilization trends of autologous hematopoietic stem cell transplantation (AHSCT) for lymphoma and multiple myeloma (MM) in China, utilizing data from 211 AHSCT…
-
APASL Lecture Hall | Prof. Jun Li: Latest Developments in ACLF Early Warning Models, Leading the Way with Large Sample Data from China
ACLF, with its complex triggers and unclear pathogenesis, exhibits high mortality rates under internal medicine comprehensive treatment. In European and American populations, alcoholic liver cirrhosis predominates (60.3%), with severe bacterial…
-
Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation
In September 2023, a study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published in Hematological Oncology, focused on the effectiveness of azacytidine (AZA) maintenance therapy post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML). Through propensity score matching, the research…
Connecting Medical Expertise through Media